As for the four biomarkers, previous studies showed that FHL2 has been identified as a biomarker of lung cancer and elevated level of FHL2 exacerbates the outcome of patients with non-small cell lung cancer (NSCLC) and the malignant phenotype in NSCLC cells43. This evidence concerns the gene FHL2 and lung cancer.